Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV004799320 | SCV001431132 | uncertain significance | Developmental and epileptic encephalopathy, 27 | 2022-01-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002402797 | SCV002707681 | uncertain significance | Inborn genetic diseases | 2017-09-29 | criteria provided, single submitter | clinical testing | The p.E55K variant (also known as c.163G>A), located in coding exon 1 of the GRIN2B gene, results from a G to A substitution at nucleotide position 163. The glutamic acid at codon 55 is replaced by lysine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species; however, lysine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV002570577 | SCV003257930 | benign | Intellectual disability, autosomal dominant 6; Developmental and epileptic encephalopathy, 27 | 2024-12-16 | criteria provided, single submitter | clinical testing |